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ABSTRACT
Introduction: Highly active antiretroviral
therapy (HAART) is effective and well
tolerated, but hepatotoxicity is relatively
common. Different non-invasive methods are
available for detecting liver fibrosis in patients
with chronic liver disease.
Methods: Patients who were HIV positive and
who had given their informed consent were
included in this cross-sectional study. Transient
elastography [FibroScan (FS); Echosens], serum
hyaluronic acid (HA), Hepascore (HS), Fibrosis-4
(FIB-4), and aspartate aminotransferase to
platelet ratio index (APRI) were used to detect
liver fibrosis in the patients. The agreement
between FS and the other methods was
evaluated. To observe the hepatotoxicity of
HAART, patients with chronic viral hepatitis B
or C were excluded by detection of hepatitis B
surface antigens and hepatitis C virus
antibodies. Patients with chronic alcohol
intake were excluded by measuring
carbohydrate-deficient transferrin (CDT). FS
correlation with the duration of therapy with
protease inhibitors (PI), nucleoside reverse
transcriptase inhibitors (NRTI), and non-
nucleoside reverse transcriptase inhibitors
(NNRTI) was evaluated.
Results: Overall, 203 patients were included in
the study. The agreement between the different
tests ranged from 64% to 77%: FS vs. HA, 72%;
FS vs. APRI, 74%; FS vs. HS, 77%; and FS vs. FIB-
4, 64%. After excluding patients with chronic
hepatitis B or C and elevated CDT, 153 patients
remained for studying the hepatotoxicity of
HAART. A significant correlation of FS with the
duration of medication intake was observed for
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PIs (P = 0.026; r = 0.18). NRTI and NNRTI
therapy duration did not correlate with FS.
Conclusions: The agreement between FS and
other tests ranged from 64% to 77%. A
significant correlation was found between liver
stiffness and the duration of therapy with PIs,
which underlines the known hepatotoxicity of
this substance group.
Funding: Heinz-Ansmann Foundation.
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INTRODUCTION
Highly active antiretroviral therapy (HAART)
has dramatically changed the course of HIV
infection, with a decrease in morbidity and
mortality derived from classical opportunistic
infections [1–3]. Abnormal liver function tests
are common and may be caused by HIV itself,
hepatitis viruses, systemic opportunistic
infections, malignancies, and drug-induced
hepatotoxicity [4–7]. There are four major
classes of HAART: nucleoside reverse
transcriptase inhibitors (NRTI), non-nucleoside
reverse transcriptase inhibitors (NNRTI),
protease inhibitors (PI), and integrase
inhibitors.
Hepatotoxicity, liver enzyme elevation, and
drug interactions are significant problems in
patients with HIV who are on HAART [8, 9]. In
patients commencing antiretroviral therapy,
14–20% will experience elevations of liver
enzymes and 2–10% will require interruption
of antiretroviral therapy due to severe hepatic
injury and a marked elevation of liver enzymes
[10, 11]. There are multiple pathogenetic
mechanisms involved in hepatotoxicity,
including direct drug toxicity, immune
reconstitution in the presence of hepatitis C
virus (HCV) and/or hepatitis B virus (HBV) co-
infections, hypersensitivity reactions with liver
involvement, and mitochondrial toxicity [12].
Other pathogenetic pathways may be involved,
such as insulin resistance caused by several
antiretrovirals, which may contribute to the
development of steatohepatitis. The
relationship between drug toxicity and the
development of liver fibrosis or liver cirrhosis
is still unclear.
Different non-invasive methods have been
described to detect liver fibrosis or liver
cirrhosis. Most of these scores use serum
markers [13]. In the past few years, transient
elastography [FibroScan (FS); Echosens] has
gained an important role in the detection of
liver fibrosis. FS is a simple, non-invasive
method of assessing liver fibrosis by measuring
liver stiffness [14]. A good correlation has been
found between the stage of liver fibrosis and the
measured liver stiffness [15–17].
In this study, the authors compared different
non-invasive methods of detecting liver
fibrosis/cirrhosis in patients who were HIV
positive. Furthermore, to identify the drug
classes that are associated with liver damage
the duration of medication intake was
correlated with the results of FS.
METHODS
Patients
Patients who were HIV positive and who had
given their informed consent were included
into this cross-sectional study performed at the
University of Du¨sseldorf, Germany. Diagnosis of
HIV infection was confirmed by detection of
HIV antibodies by western blot. The clinical
stage of HIV infection was classified according
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to the revised Centers for Disease Control and
Prevention (CDC) staging system. The study
protocol was approved by the ethics committee
of the University of Du¨sseldorf.
Liver Stiffness Measured by FS
Details of the technical background and
examination procedure have been described
previously [14]. Patients had been fasting for
at least 8 h when FS was performed. Blood tests
were taken just before performance of FS. The
tip of the probe transducer was placed on the
skin between the rib bones and the level of the
right lobe of the liver. The measurement depth
was between 25 and 65 mm below the skin
surface. Ten measurements were performed
with success rates of at least 60% and the
interquartile range did not exceed 30% of the
median value. The results were expressed in
kiloPascal (kPa). The median value was taken as
representative. A good correlation has been
established with Metavir scores as follows: F0–
F1, \7.1 kPa; F2–F3, 7.1–12.5 kPa; and F4,
[12.5 kPa [16].
Aspartate Aminotransferase to Platelet
Ratio Index
The aspartate aminotransferase (AST) to platelet
ratio index (APRI) was calculated using the
formula APRI = AST level/(upper limit of
normal [ULN]) 9 100/platelet count (109/L)
and categorized according to cutoffs defined
by Wai et al. [18]:\0.5, no significant fibrosis;
0.5–1.5 fibrosis;\1.5, cirrhosis).
Hyaluronic Acid
Hyaluronic acid (HA) levels (ng/ml) were
assessed in serum samples, stored at -80 C,
using a commercially available enzyme-linked
immunosorbent assay (Corgenix, Broomfield,
CO, USA). The following previously published
[19] HA cutoff values were used:\75 ng/ml, no
significant fibrosis; 75–110 ng/ml, fibrosis; [
110 ng/ml, cirrhosis.
Hepascore
The Hepascore (HS) was calculated from the
following equation: y/(1 ? y); where y = exp[-
4.185818 - (0.0249 9 age) ? (0.7464 9 sex) ?
(1.0039 9 a2-macroglobulin) ? (0.0302 9 HA
? (0.0691 9 bilirubin) - (0.0012 9 gamma-glu-
tamyl transpeptidase (GGT)]; with age in
years, male sex = 1, female sex = 0, a2-
macroglobulin in g/L, HA in lg/L, bilirubin
in lmol/L, and GGT in U/L [20]. The following
HS cutoff values were used: \0.5, no fibrosis;
0.5–0.85, fibrosis;[0.85, cirrhosis.
Carbohydrate-Deficient Transferrin
Carbohydrate-Deficient Transferrin (CDT) was
taken as a marker for increased alcohol intake.
CDT performed best as an alcohol biomarker in
comparison with other biomarkers, with a
sensitivity of 67% and specificity of 71% for
detecting an average consumption of more than
40 g per day versus less [21].
Fibrosis-4
The Fibrosis-4 (FIB-4) values were calculated
automatically using the formula: age
(years) 9 AST [U/L]/(platelets [109/L] 9 (ALT
[U/L])1/2), in which the age of the patient was
the age at the time of measurement liver
stiffness. The following FIB-4 cutoff values
were used: \1.45, no fibrosis; 1.45–3.25,
fibrosis;[3.25, cirrhosis [22].
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Body Mass Index
Body mass index (BMI) was calculated using the
following equation: weight (kg)/[height (m)]2.
Serological Testing of HBV and HCV
The qualitative analysis of HCV-RNA was tested
by a commercial polymerase chain reaction
assay (Amplicor HCV Amplification 2.0, Roche
Diagnostics, Indianapolis, IN, USA). The
quantitative analysis of HCV-RNA was made
by a commercial assay (HCV-TaqMan (in-
house); limit of detection 250 U/ml). Hepatitis
B surface antigen (HBs-Ag) as a serologic marker
of HBV infection was detected by a commercial
immunoassay (Axsym HBs-Ag, Abbott
Laboratories, North Chicago, IL, USA).
Statistical Analysis
Data were entered in SPSS (version 11.0, SPSS Inc.,
Munich, Germany). A v2 or Fisher’s exact test
(F test) was used for the comparison of categorical
variables, and a Mann–Whitney test was used for
the comparison of continuous variables. The
correlation study between therapy duration and
liver stiffness was done by Pearson’s test; patients
with signs of hepatitis or cholestasis were not
included in this analysis. To compare the
agreement between the different tests of
fibrosis/cirrhosis, a kappa statistic was performed.
A logistic regression was performed to identify
independent factor that was associated with the
increase of liver stiffness. The significance level was
set at 0.05 and all P values were two tailed.
RESULTS
A total of 203 (148 men and 55 women, mean
age 47 ± 11 years) consecutive patients who
were HIV positive were enrolled in the study.
Patients’ characteristics are shown in Table 1.
Fifty-one patients were at HIV stage CDC A, 69
patients were at stage CDC B, and 83 patients
were at stage CDC C.
Table 1 Baseline characteristics
Characteristic
Male, n (%) 148 (72.9)
Age (years, mean ± SD) 47 ± 11





CD4? (cells/mm3, mean ± SD) 486 ± 263




HIV RNA undetectable, n (%) 138 (68)
ALT (U/L, mean ± SD) 25 ± 45
AST (U/L, mean ± SD) 18 ± 23
GGT (U/L, mean ± SD) 43 ± 60
Total bilirubin (mg/dL) 0.86 ± 1.53
Platelet count (9103, mean ± SD) 222 ± 68
HCV-Ab positive, n (%) 16 (7.9)
HCV-RNA positive, n (%) 8 (3.9)
HBs-Ag positive, n (%) 11 (5.4)
CDT[2.5%, n (%) 24 (11.8)
ALT alanine aminotransferase, AST aspartate
aminotransferase, CDC Centers for Disease Control and
Prevention, CDT carbohydrate-deﬁcient transferrin, GGT
gamma-glutamyl transpeptidase, HBs-Ag hepatitis B
surface antigen, HCV hepatitis C virus, HCV-Ab
hepatitis C virus antibody
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FS was successfully performed (at least 60%
success rate) in 188 (93%) of the 203 patients.
The following frequencies of fibrosis grades
were observed: no significant fibrosis (FS
\7.1 kPa), 160 (85%) patients; fibrosis (FS
7.1–12.5 kPa), 25 (13%) patients; and cirrhosis
(FS[12.5 kPa), 3 (2%) patients (Table 2).
APRI was available for 180 patients. APRI
values indicating the grade of fibrosis showed
the following results: no significant fibrosis
(APRI \0.5), 128 (71%) patients; fibrosis (APRI
0.5–1.5), 47 (26%) patients; and cirrhosis (APRI
[1.5), 5 (3%) patients.
Serum samples for detection of HA were
available for 184 patients. The following grade
of fibrosis/cirrhosis was associated with the
measured HA levels: no significant fibrosis (HA
\75 ng/ml), 143 (77%) patients; fibrosis (HA
75–110 ng/ml), 18 (10%) patients; and cirrhosis
(HA[110 ng/ml), 23 (13%) patients.
All parameters for calculation of the HS were
available for 147 patients. HS showed the
following frequencies: no significant fibrosis
(HS \0.5), 119 (81%) patients; fibrosis (HS
0.5–0.85), 13 (9%) patients; and cirrhosis (HS
[0.85), 15 (10%) patients.
FIB-4 was available for 187 patients. FIB-4
values indicating the grade of fibrosis showed
the following results: no significant fibrosis
(FIB-4\1.45), 116 (62%) patients; fibrosis (FIB-
4 1.45–3.25), 61 (33%) patients; and cirrhosis
(FIB-4[3.25), 10 (5%) patients.
To study agreement between FS and the
other tests, a kappa statistical procedure was
performed. A total of 184 patients underwent
liver stiffness measurement and HA was
detected concomitantly. The stage of fibrosis
agreed in 132 (72%) patients (j = 0.2). A
consistent result was found in 133 (74%) of
the 180 patients who underwent both FS and
APRI (j = 0.33). A similar percentage was
observed by the comparison between FS and
HS. Both methods of fibrosis/cirrhosis detection
were performed in 147 patients. The same stage
of fibrosis/cirrhosis was detected in 113 (77%) of
these patients (j = 0.35). A total of 180 patients
underwent liver stiffness measurement and FIB-
4 was detected concomitantly. The stage of
fibrosis agreed in 115 (64%) patients (j = 0.19).
To investigate the influence of HAART on
the liver stiffness, the liver stiffness was
correlated with the duration (months) of
medication for each substance group (NRTI,
NNRT, and PI). Based on the fact that only four
patients received integrase inhibitors, this
substance group was not correlated with FS.
All patients with any positive marker for HBV
(HBs-Ag positive, n = 11) or HCV (hepatitis C
virus antibody positive, n = 16; HCV-RNA
positive, n = 8) infection were excluded. CDT
was taken as a marker for increased alcohol
intake. Patients with a CDT above the ULN
(2.5%) were also excluded. A total of 153
patients remained for the analysis. Liver
Table 2 Frequencies of the different ﬁbrosis stages
Test No signiﬁcant ﬁbrosis Fibrosis Cirrhosis Correlation (j)
FS (n = 188) 160 (85%) 25 (13%) 3 (2%) Reference
APRI (n = 180) 128 (71%) 47 (26%) 5 (3%) 0.33
HA (n = 184) 143 (71%) 18 (10%) 23 (13%) 0.2
HS (n = 147) 119 (81%) 13 (9%) 15 (10%) 0.35
APRI aspartate aminotransferase to platelet ratio index, FS FibroScan, HA hyaluronic acid, HS Hepascore
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stiffness was below 7.1 kPa in 134 (87.7%)
patients, was between 7.1 and 12.5 kPa in 18
(11.7%) patients, and was above 12.5 kPa in one
patient (0.6%). Statistical analyses were only
done between patients with a liver stiffness
below 7.1 kPa and patients with a liver stiffness
between 7.1 and 12.5 kPa (Table 3).
Therapy duration with each substance group
was correlated with the measured liver stiffness.
Therapy duration with PI ranged from 0 to
124 months (mean 28 ± 31 months). Liver
stiffness showed a positive, statistically
significant correlation with the duration of PI
intake (r = 0.18; P = 0.026; Table 4). Therapy
duration of NRTI (mean 55 ± 44 months; range
0–188 months; r = 0.044; P = 0.59) and NNRTI
(mean 24 ± 28 months; range 0–105 months;
r = -0.6; P = 0.461) did not correlate with liver
stiffness. No significant correlation could be
observed between liver stiffness and age
(P = 0.25), sex (P = 0.12), race (P = 0.13 for
white patients vs. black patients), or BMI
(P = 0.22), so these factors could be excluded
as being confounding. To identify therapy
duration with PI as an independent factor for
the increase of liver stiffness, a logistic
regression was performed including the factors
BMI, age, sex, race, and therapy duration with
PI. Therapy duration was the only factor that
was significantly associated with liver stiffness
[P = 0.049; 95% confidence interval (CI)
0.056–0.964].
DISCUSSION
HAART has dramatically changed the course of
HIV infection, and has decreased the morbidity
and mortality derived from classical
opportunistic infections [23]. Therapy is
effective in most cases and well tolerated in a
substantial proportion of patients, but adverse
events, such as hypersensitivity reactions and
hepatotoxicity, are relatively common [24, 25].
Therapy with PIs is more often associated with
liver enzyme elevation than with NRTIs or
NNRTIs. Long-term effects of HAART in
developing liver fibrosis/cirrhosis have not
been sufficiently studied. This may in part be
explained by the fact that liver biopsy is the
gold standard for the detection of liver
fibrosis/cirrhosis, but is an invasive method
with associated complications [26].
Furthermore, to study the development of
liver fibrosis under HAART, repeated liver
biopsies are difficult to justify due to the
associated risk and discomfort. Different non-
invasive methods are available to detect liver
fibrosis/cirrhosis. Being aware that these tests
Table 3 Liver stiffness in dependence of duration of
medication intake
Therapy Therapy duration






PI 26.2 ± 32.1 36.6 ± 39.3 0.21
NRTI 54.5 ± 44.9 56.1 ± 39.5 0.64
NNRTI 23.6 ± 27.5 25.6 ± 32.5 0.99
NNRTI non-nucleoside reverse transcriptase inhibitors,
NRTI nucleoside reverse transcriptase inhibitors, PI
protease inhibitor
Table 4 Correlation of therapy duration with liver
stiffness
Therapy Therapy duration
(months, mean – SD)
P value
PI 28 ± 31 (range 0–124) 0.026
NRTI 55 ± 44 (range 0–188) 0.59
NNRTI 24 ± 28 (range 0–105) 0.09
NNRTI non-nucleoside reverse transcriptase inhibitors,
NRTI nucleoside reverse transcriptase inhibitors, PI
protease inhibitor
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were predominantly evaluated in patients with
hepatitis C or alcoholic liver disease, these easy-
to-handle tests were used to detect HAART-
associated liver fibrosis. Moreover, the
agreement between different non-invasive
methods (FS, HS, HA, and APRI) were
compared. FS is not reliable in patients who
are not fasting, with acute hepatitis, or
cholestasis [27–29]. Taking this into account,
only patients who were fasting and had no sign
of acute hepatitis or cholestasis were included
in the current study.
A total of 203 patients were included in this
cross-sectional analysis. In the first step, the
extent of agreement between the different tests
was compared. Based on the fact that FS has
been evaluated in liver diseases of different
origin, FS was chosen as the reference. The
comparison between the methods showed a
comparable stage of fibrosis in 64% to 77% of
patients. This comparison between these
methods is limited by the fact that HS, HA,
FIB-4, and APRI are not designed to assess fatty
liver disease. An excellent correlation has been
shown for non-alcoholic fatty liver disease and
FS [30].
To study the role of the different substance
groups (PI, NRTI, and NNRTI) in developing
liver fibrosis/cirrhosis, FS was correlated with
the duration of medication intake for each
group. Because of the limited number of
patients who received integrase inhibitors, the
effect of this substrate group could not be
studied. Additional factors, which may lead to
liver fibrosis/cirrhosis, were largely eliminated
by excluding patients with chronic HBV or HCV
infection and patients with evidence of chronic
alcohol abuse. A total of 153 patients remained
for this analysis. We found a significant
correlation of the liver stiffness with the
duration of PI intake, but not with the
duration of NTRI or NNRTI intake. To exclude
age, sex, race, and BMI as confounding factors a
multivariable analysis including these factors
was performed. All these factors could be
excluded as relevant factors for hepatotoxicity.
Hepatotoxicity is a well-recognized side
effect of PI therapy with over 50% of patients
developing asymptomatic mild elevation of
transaminases [31]. In some series, up to
10–20% developed severe hepatotoxicity with
liver enzyme elevation above 5 times the ULN
[31]. Sulkowski et al. [31] observed severe (liver
enzyme elevation above 3 times the ULN)
hepatotoxicity in 31 (10.4%) of 298 patients
(95% CI 7.2–14.4%) [31]. Transaminases usually
rise after 3 months of therapy and will return to
normal over the next 3–5 months in most cases;
however, approximately 10% remain
persistently elevated [32].
The histological pattern observed in patients
with PI hepatotoxicity is variable without
definite pathognomonic features. Features
include bile duct injury and proliferation,
hepatocellular necrosis, and Mallory bodies.
Ballooning of hepatocytes, Kupffer cell
activation, and peri-cellular fibrosis in zone 3
have recently been described as features of PI
hepatotoxicity [33–35]. Different mechanisms
of hepatotoxicity such as mitochondrial
damage, hypersensitivity reactions, and
inhibition of several cytochrome P450
isoforms may be involved. The PIs, in
particular ritonavir, are potent inhibitors of
cytochrome P450 and thus may alter plasma
levels of drugs that share the same routes of
metabolism [36]. Dose-dependent
hepatotoxicity may result from toxic levels of
drugs whose clearance is reduced. The results of
the current study underline the hepatotoxicity
of PIs and the association of long-term drug use
with the development of liver fibrosis. This
correlation has to be investigated in a longer
prospective study. The acceptance of repeated
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measurements with the non-invasive methods
can be improved, so that prospective studies to
detect drug induced hepatotoxicity can be
performed. The weakness of the current study
is that it is a cross-sectional study. All patients
underwent FS once, so that possible progression
of the liver stiffness could not be detected.
Furthermore, possible factors like co-
medication intake such as statin or
antihypertensive drugs were not considered.
Switches to other antiretroviral therapy
regimes were also not incorporated.
Hepatotoxicity is a serious complication in
patients taking HAART. Here, an agreement of
the stage of liver fibrosis/cirrhosis in 64% to
77% using different non-invasive methods was
demonstrated. After exclusion of known factors
which can trigger liver fibrosis/cirrhosis, a
correlation of FS with the duration of PI intake
was observed. FS can be used to detect the
development of liver fibrosis/cirrhosis in
patients taking HAART, particularly in patients
receiving a therapy regime that includes PI.
CONCLUSION
The agreement between FS and the other tests
was 64% to 77%. A significant correlation was
found for liver stiffness and the duration of
therapy with PI, which underlines the known
hepatotoxicity of this substance group. Patients
receiving PI should be monitored to detect
hepatotoxicity and avoid long-term
complications such as liver cirrhosis. FS is a
simple method of assessing liver fibrosis and can
be used in regular clinical routine.
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